{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-024911","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.153846+00:00","generated_at":"2026-05-21T16:09:07.957498+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ovid Therapeutics Q1 net loss $10.2M; OV329 data on track for Q3 2025","bullets":["Cash and equivalents $43.0M at March 31, 2025; expected to fund operations into 2H 2026.","Topline Phase 1 biomarker and safety data for OV329 (GABA-AT inhibitor) expected in Q3 2025.","OV350 KCC2 direct activator dosed in Phase 1 in Q1 2025; safety/tolerability results expected Q4 2025.","Q1 net loss $10.2M ($0.14/sh) vs $11.7M ($0.17/sh) a year ago; total op expenses down 28% to $12.7M.","Oral KCC2 candidate OV4071 on track to initiate proof-of-concept study in H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-024911","json":"https://secwatch.observer/filing/0001628280-25-024911.json","markdown":"https://secwatch.observer/filing/0001628280-25-024911.md","text":"https://secwatch.observer/filing/0001628280-25-024911.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828025024911/0001628280-25-024911-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828025024911/ovid-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T16:09:07.957498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}